Lista de obras -

A Podocyte-Based Automated Screening Assay Identifies Protective Small Molecules

artículo científico publicado en 2015

A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation

artículo científico publicado en 2014

A tripartite complex of suPAR, APOL1 risk variants and αvβ3 integrin on podocytes mediates chronic kidney disease.

artículo científico publicado en 2017

Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children

artículo científico publicado en 2017

BDNF repairs podocyte damage by microRNA-mediated increase of actin polymerization

artículo científico publicado en 2015

Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease

artículo científico publicado en 2016

CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival

scientific journal article

CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival

artículo científico publicado en 2012

CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance

artículo científico publicado en 2013

Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study.

artículo científico publicado en 2017

Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis

artículo científico publicado en 2014

Circulating CD40 autoantibody and suPAR synergy drives glomerular injury

artículo científico publicado en 2015

Circulating suPAR in two cohorts of primary FSGS.

artículo científico publicado en 2012

Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis

artículo científico publicado en 2011

Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial

artículo científico publicado en 2015

Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group

artículo científico publicado en 2015

In vivo electroporation and non-protein based screening assays to identify antibodies against native protein conformations

artículo científico publicado en 2011

Is there clinical value in measuring suPAR levels in FSGS?

artículo científico publicado en 2013

Minimal change disease as a modifiable podocyte paracrine disorder ⬇️

artículo científico publicado el 17 de marzo de 2011

Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models

artículo científico publicado en 2015

Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy

artículo científico publicado en 2013

Podocyte foot process effacement in postreperfusion allograft biopsies

artículo científico publicado en 2014

Podocyte foot process effacement in postreperfusion allograft biopsies correlates with early recurrence of proteinuria in focal segmental glomerulosclerosis

artículo científico publicado en 2012

Podocyte-specific overexpression of wild type or mutant trpc6 in mice is sufficient to cause glomerular disease

artículo científico publicado en 2010

Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease

artículo científico publicado en 2007

Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation

artículo científico publicado en 2015

Reduction of proteinuria through podocyte alkalinization

artículo científico publicado en 2014

Regarding Maas's editorial letter on serum suPAR levels

artículo científico publicado en 2012

Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome

scientific article published on 05 June 2013

Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis

artículo científico publicado en 2011

Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease

artículo científico publicado en 2011

Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis.

artículo científico publicado en 2017

Soluble Urokinase Receptor and Acute Kidney Injury

artículo científico publicado en 2020

Soluble Urokinase Receptor and Chronic Kidney Disease.

artículo científico publicado en 2015

Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease

artículo científico publicado en 2014

TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function

scientific journal article

The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury

artículo científico publicado en 2012

uPAR isoform 2 forms a dimer and induces severe kidney disease in mice

scientific article published on 02 April 2019

Lista de obras de

A Podocyte-Based Automated Screening Assay Identifies Protective Small Molecules

A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation

A tripartite complex of suPAR, APOL1 risk variants and αvβ3 integrin on podocytes mediates chronic kidney disease.

Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children

BDNF repairs podocyte damage by microRNA-mediated increase of actin polymerization

Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease

CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival

CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival

CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance

Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study.

Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis

Circulating CD40 autoantibody and suPAR synergy drives glomerular injury

Circulating suPAR in two cohorts of primary FSGS.

Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis

Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial

Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group

In vivo electroporation and non-protein based screening assays to identify antibodies against native protein conformations

Is there clinical value in measuring suPAR levels in FSGS?

Minimal change disease as a modifiable podocyte paracrine disorder ⬇️

Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models

Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy

Podocyte foot process effacement in postreperfusion allograft biopsies

Podocyte foot process effacement in postreperfusion allograft biopsies correlates with early recurrence of proteinuria in focal segmental glomerulosclerosis

Podocyte-specific overexpression of wild type or mutant trpc6 in mice is sufficient to cause glomerular disease

Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease

Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation

Reduction of proteinuria through podocyte alkalinization

Regarding Maas's editorial letter on serum suPAR levels

Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome

Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis

Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease

Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis.

Soluble Urokinase Receptor and Acute Kidney Injury

Soluble Urokinase Receptor and Chronic Kidney Disease.

Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease

TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function

The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury

uPAR isoform 2 forms a dimer and induces severe kidney disease in mice